Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial.

Item

http://www.wikidata.org/entity/Q54703477

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Inter-institutional heterogene ...... the JCOG9912 phase III trial.

@en

Inter-institutional heterogene ...... the JCOG9912 phase III trial.

@nl

type

Item

label

Inter-institutional heterogene ...... the JCOG9912 phase III trial.

@en

Inter-institutional heterogene ...... the JCOG9912 phase III trial.

@nl

prefLabel

Inter-institutional heterogene ...... the JCOG9912 phase III trial.

@en

Inter-institutional heterogene ...... the JCOG9912 phase III trial.

@nl

P1476

Inter-institutional heterogene ...... the JCOG9912 phase III trial.

@en

P2093

A Ohtsu

http://www.w3.org/2001/XMLSchema#string

H Fukuda

http://www.w3.org/2001/XMLSchema#string

J Mizusawa

http://www.w3.org/2001/XMLSchema#string

K Nakamura

http://www.w3.org/2001/XMLSchema#string

N Boku

http://www.w3.org/2001/XMLSchema#string

T Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Y Kurokawa

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Impact of hospital volume on operative mortality for major cancer surgery.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

Effect of surgical work volume on postoperative complication: superiority of specialized center in gastric cancer treatment.

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

P304

e000031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ESMOOPEN-2015-000031

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27843586

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

5070211

http://www.w3.org/2001/XMLSchema#string